ABOUT THE EXPERT
Bruce D. Cheson,
MD, FACP, FAAAS, FASCO
Frank M. Ewing Foundation Chair in Hematology-Oncology
Professor of Medicine
Head of Hematology and Cellular Therapy
Deputy Chief, Division of Hematology and Oncology
Fellowship Program Director
Georgetown Lombardi Comprehensive Cancer Center
MedStar Georgetown University Hospital
Bruce D. Cheson, MD, FACP, FAAS, FASCO, attended the University of Virginia and Tufts University Medical School. He completed his internship and residency in Internal Medicine at the University of Virginia Hospitals, followed by a clinical and research fellowship in Hematology at New England Medical Center Hospital (currently known as Tufts Medical Center). From 1977 to 1984, he was assistant professor of Medicine in the Division of Hematology/Oncology at the University of Utah. From 1986 to 2002, he was Head, Medicine Section, Cancer Therapy Evaluation Program at the National Cancer Institute. Currently, Dr Cheson is Frank M. Ewing Foundation Chair in Hematology-Oncology, professor of Medicine, head of Hematology and Cellular Therapy, and deputy chief, Division of Hematology and Oncology, and fellowship program director at MedStar Georgetown University Hospital, Georgetown Lombardi Comprehensive Cancer Center.
Dr Cheson has authored more than 600 medical publications and abstracts, and has contributed to over 60 texts. He is currently editor-in-chief of Annals of Lymphoma, formerly associate editor of the Journal of Clinical Oncology, and editor-in-chief of Clinical Lymphoma, Myeloma & Leukemia. He was the former editor-in-chief of Clinical Advances in Hematology & Oncology. He also serves on the editorial boards of numerous journals.
Dr Cheson has served on several committees of the American Society of Clinical Oncology (ASCO) and was on its Board of Directors, and has edited ASCO News and ASCO Daily News. He has also served as the editor of the ASCO-SEP® and American College of Physician’s Medical Knowledge Self-Assessment Program in Oncology. From 2002 to 2006, he was on the Oncologic Drug Advisory Committee to the US Food and Drug Administration. He is past-chair of the Lymphoma Committee of the Cancer and Leukemia Group B/Alliance, the Scientific Advisory Board of the Lymphoma Research Foundation, and the American Joint Committee on Cancer Subcommittee on Lymphoma. Dr Cheson’s clinical interests focus on the development and evaluation of new therapeutic approaches for hematologic malignancies.